Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is conducted to determine the safety, tolerability, and efficacy of NOX-H94 in
patients with anemia of chronic disease (ACD). Furthermore, this study is intended to provide
data needed to correlate plasma concentrations of NOX-H94 with its efficacy and to choose the
appropriate dose and dose schedule of subsequent efficacy studies.
Some chronic diseases, e.g. tumors, inflammation, renal disease, are associated with high
hepcidin concentrations in the blood. These hepcidin concentrations cause a reduction in iron
concentrations in the blood and subsequently impair formation of red blood cells. Treatment
with NOX-H94 is expected to inhibit this patho-mechanism by binding and inactivating
hepcidin.